These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10514279)

  • 1. Discovery of potent and selective SH2 inhibitors of the tyrosine kinase ZAP-70.
    Vu CB; Corpuz EG; Merry TJ; Pradeepan SG; Bartlett C; Bohacek RS; Botfield MC; Eyermann CJ; Lynch BA; MacNeil IA; Ram MK; van Schravendijk MR; Violette S; Sawyer TK
    J Med Chem; 1999 Oct; 42(20):4088-98. PubMed ID: 10514279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solution structure of the C-terminal SH2 domain of the human tyrosine kinase Syk complexed with a phosphotyrosine pentapeptide.
    Narula SS; Yuan RW; Adams SE; Green OM; Green J; Philips TB; Zydowsky LD; Botfield MC; Hatada M; Laird ER
    Structure; 1995 Oct; 3(10):1061-73. PubMed ID: 8590001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of electrostatic interactions in SH2 domain recognition: salt-dependence of tyrosyl-phosphorylated peptide binding to the tandem SH2 domain of the Syk kinase and the single SH2 domain of the Src kinase.
    Grucza RA; Bradshaw JM; Mitaxov V; Waksman G
    Biochemistry; 2000 Aug; 39(33):10072-81. PubMed ID: 10955995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The N-terminal SH2 domains of Syk and ZAP-70 mediate phosphotyrosine-independent binding to integrin beta cytoplasmic domains.
    Woodside DG; Obergfell A; Talapatra A; Calderwood DA; Shattil SJ; Ginsberg MH
    J Biol Chem; 2002 Oct; 277(42):39401-8. PubMed ID: 12171941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of non-peptidic inhibitors for the Syk C-terminal SH2 domain based on structure-based in-silico screening.
    Niimi T; Orita M; Okazawa-Igarashi M; Sakashita H; Kikuchi K; Ball E; Ichikawa A; Yamagiwa Y; Sakamoto S; Tanaka A; Tsukamoto S; Fujita S; Tatsuta K; Maeda Y; Chikauchi K
    J Med Chem; 2001 Dec; 44(26):4737-40. PubMed ID: 11741491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the roles of SH2 domain-containing proteins in T-lymphocyte activation by using dominant negative SH2 domains.
    Northrop JP; Pustelnik MJ; Lu AT; Grove JR
    Mol Cell Biol; 1996 May; 16(5):2255-63. PubMed ID: 8628292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the interaction of ZAP-70 and syk protein-tyrosine kinases with the T-cell antigen receptor by plasmon resonance.
    Bu JY; Shaw AS; Chan AC
    Proc Natl Acad Sci U S A; 1995 May; 92(11):5106-10. PubMed ID: 7761456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the design and synthesis of SH2 inhibitors of Src, Grb2 and ZAP-70.
    Vu CB
    Curr Med Chem; 2000 Oct; 7(10):1081-100. PubMed ID: 10911019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modification by covalent reaction or oxidation of cysteine residues in the tandem-SH2 domains of ZAP-70 and Syk can block phosphopeptide binding.
    Visperas PR; Winger JA; Horton TM; Shah NH; Aum DJ; Tao A; Barros T; Yan Q; Wilson CG; Arkin MR; Weiss A; Kuriyan J
    Biochem J; 2015 Jan; 465(1):149-61. PubMed ID: 25287889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonpeptidic SH2 inhibitors of the tyrosine kinase ZAP-70.
    Vu CB; Corpuz EG; Pradeepan SG; Violette S; Bartlett C; Sawyer TK
    Bioorg Med Chem Lett; 1999 Oct; 9(20):3009-14. PubMed ID: 10571165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for Syk tyrosine kinase ubiquity in signal transduction pathways revealed by the crystal structure of its regulatory SH2 domains bound to a dually phosphorylated ITAM peptide.
    Fütterer K; Wong J; Grucza RA; Chan AC; Waksman G
    J Mol Biol; 1998 Aug; 281(3):523-37. PubMed ID: 9698567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Syk and ZAP-70 mediate recruitment of p56lck/CD4 to the activated T cell receptor/CD3/zeta complex.
    Thome M; Duplay P; Guttinger M; Acuto O
    J Exp Med; 1995 Jun; 181(6):1997-2006. PubMed ID: 7539035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ZAP-70 binding specificity to T cell receptor tyrosine-based activation motifs: the tandem SH2 domains of ZAP-70 bind distinct tyrosine-based activation motifs with varying affinity.
    Isakov N; Wange RL; Burgess WH; Watts JD; Aebersold R; Samelson LE
    J Exp Med; 1995 Jan; 181(1):375-80. PubMed ID: 7528772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antagonists of the Src homology 2 (SH2) domains of Grb2, Src, Lck and ZAP-70.
    García-Echeverria C
    Curr Med Chem; 2001 Nov; 8(13):1589-604. PubMed ID: 11562287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein tyrosine kinases Syk and ZAP-70 display distinct requirements for Src family kinases in immune response receptor signal transduction.
    Zoller KE; MacNeil IA; Brugge JS
    J Immunol; 1997 Feb; 158(4):1650-9. PubMed ID: 9029101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystal structure and NMR studies of the apo SH2 domains of ZAP-70: two bikes rather than a tandem.
    Folmer RH; Geschwindner S; Xue Y
    Biochemistry; 2002 Dec; 41(48):14176-84. PubMed ID: 12450381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphotyrosine-containing dipeptides as high-affinity ligands for the p56lck SH2 domain.
    Llinaś-Brunet M; Beaulieu PL; Cameron DR; Ferland JM; Gauthier J; Ghiro E; Gillard J; Gorys V; Poirier M; Rancourt J; Wernic D; Betageri R; Cardozo M; Jakes S; Lukas S; Patel U; Proudfoot J; Moss N
    J Med Chem; 1999 Feb; 42(4):722-9. PubMed ID: 10052978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective Binders of the Tandem Src Homology 2 Domains in Syk and Zap70 Protein Kinases by DNA-Programmed Spatial Screening.
    Marczynke M; Gröger K; Seitz O
    Bioconjug Chem; 2017 Sep; 28(9):2384-2392. PubMed ID: 28767218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dephosphorylation of ZAP-70 and inhibition of T cell activation by activated SHP1.
    Brockdorff J; Williams S; Couture C; Mustelin T
    Eur J Immunol; 1999 Aug; 29(8):2539-50. PubMed ID: 10458769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and development of spleen tyrosine kinase (SYK) inhibitors.
    Singh R; Masuda ES; Payan DG
    J Med Chem; 2012 Apr; 55(8):3614-43. PubMed ID: 22257213
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.